Compare · LIVN vs MASI
LIVN vs MASI
Side-by-side comparison of LivaNova PLC (LIVN) and Masimo Corporation (MASI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and MASI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.42B, about 2.2x LIVN ($4.37B).
- Over the past year, LIVN is up 40.3% and MASI is up 25.7% - LIVN leads by 14.6 points.
- LIVN has hit the wire 7 times in the past 4 weeks while MASI has been quiet.
- MASI has more recent analyst coverage (24 ratings vs 20 for LIVN).
- Company
- LivaNova PLC
- Masimo Corporation
- Price
- $79.41+1.50%
- $179.96+0.00%
- Market cap
- $4.37B
- $9.42B
- 1M return
- -1.38%
- +0.93%
- 1Y return
- +40.34%
- +25.72%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 7
- 0
- Recent ratings
- 20
- 24
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest LIVN
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- SEC Form 3 filed by new insider Folli Stefano
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
Latest MASI
- SEC Form 15-12G filed by Masimo Corporation
- Director Solomon Darlene J. S. returned $542,700 worth of shares to the company (3,015 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- Director Scannell Timothy J returned $469,440 worth of shares to the company (2,608 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- Director Lane Wendy E returned $469,440 worth of shares to the company (2,608 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director by deputization Politan Capital Management Lp
- Director by deputization Politan Capital Management Lp returned $826,357,140 worth of shares to the company (4,590,873 units at $180.00) (SEC Form 4)
- Chairman of the Board Brennan Michelle returned $1,675,620 worth of shares to the company (9,309 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Accounting Officer Hataishi Paul returned $2,397,060 worth of shares to the company (13,317 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- EVP, Operations Sampath Anand returned $6,102,180 worth of shares to the company (33,901 units at $180.00), closing all direct ownership in the company (SEC Form 4) to cover taxes
- SEC Form 4 filed by Chief Commercial Officer Meehan Greg Allen (for tax liability)